Fatty acid-like Pt(iv) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36. Issue 73 (13th August 2020)

• Record Type: Journal Article
• Authors: Jayawardhana, Amarasooriya M. D. S.; Stilgenbauer, Morgan; Datta, Payel; Qiu, Zihan; Mckenzie, Sarine; Wang, Han; Bowers, David; Kurokawa, Manabu; Zheng, Yao-Rong
• Is Part Of: Chemical communications. Volume 56:Issue 73(2020)
• Page Start: 10706
• Page End: 10709
• Publication Date: 2020-08-13
• Subjects: Chemistry -- Periodicals; 540
• DOI: 10.1039/d0cc02174a
• Languages: English
• ISSNs: 1359-7345

Abstract

Abstract : The fatty acid-like Pt(iv ) prodrugs act as a "Trojan horse" to exploit upregulated CD36 receptors to facilitate their entry to ovarian cancer cells. Abstract : Resistance to the platinum-based chemotherapy drug, cisplatin, is a significant setback in ovarian cancer. We engineered fatty acid-like Pt(iv ) prodrugs that harness the fatty acid transporter CD36 to facilitate their entry to ovarian cancer cells. We show that these novel constructs effectively kill cisplatin-resistant ovarian cancer cells.